|Bid||1.565 x 0|
|Ask||1.610 x 0|
|Day's range||1.575 - 1.622|
|52-week range||1.190 - 2.060|
|PE ratio (TTM)||N/A|
|Earnings date||28 Aug. 2018 - 3 Sep. 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||2.86|
The shares of Altium Limited (ASX:ALU), Mesoblast Limited (ASX:MSB), and Santos Ltd (ASX:STO) will be on watch on Wednesday. Here's why...
NEW YORK and MELBOURNE, Australia, July 17, 2018-- Mesoblast Limited today announced that it has entered into a strategic alliance with one of China’ s largest pharmaceutical companies, Tasly Pharmaceutical ...
Mesoblast Limited (MESO) (ASX:MSB) today announced that Shawn Cline Tomasello has joined its Board of Directors. With more than 30 years’ experience in the pharmaceutical and biotech industries, Ms Tomasello brings substantial commercial and transactional experience to the Mesoblast board. Since 2015, Ms Tomasello has been Chief Commercial Officer at leading immuno-oncology cell therapy company Kite Pharma, where she played a pivotal role in the company’s acquisition in 2017 by Gilead Sciences for $11.9 billion.
Mesoblast Limited (MESO) (ASX:MSB) today announced a US$50 million financing from NovaQuest Capital Management, L.L.C. (NovaQuest) for the continued development and commercialization of its allogeneic product candidate remestemcel-L (MSC-100-IV) for children with steroid refractory acute Graft versus Host Disease (aGVHD). Mesoblast Chief Executive Dr Silviu Itescu stated: “We are pleased to have NovaQuest’s support for our plans to bring remestemcel-L to market. This transaction is underpinned by the strength of our GVHD Phase 3 clinical trial results.
NEW YORK and MELBOURNE, Australia, June 21, 2018-- Mesoblast Limited today announced key Day 100 survival outcomes of its Phase 3 trial for remestemcel-L, an allogeneic mesenchymal stem cell product candidate, ...
Mesoblast Limited (MESO) (ASX:MSB) today announced that Joseph R. Swedish has joined its Board of Directors. Mr. Swedish has more than two decades of healthcare leadership experience as the CEO for major U.S. healthcare organizations. Prior to joining Anthem, Mr. Swedish was CEO for several major integrated healthcare delivery systems, including Trinity Health and Colorado’s Centura Health.
MELBOURNE, Australia and NEW YORK, May 30, 2018-- Mesoblast Limited today announced strong financial results for the nine months ended March 31, 2018 and provided operational highlights for the third quarter ...
Mesoblast Limited (ASX:MSB) (MESO) today announced the appointment of Josh Muntner as its new Chief Financial Officer, based in New York. Chief Executive Dr Silviu Itescu welcomed the appointment of Mr Muntner stating he would bring substantial U.S. corporate finance, transactional and capital markets experience to Mesoblast. Mr Muntner has accrued 20 years’ experience in healthcare investment banking and corporate finance, and has been involved in a wide range of healthcare-related transactions with approximately $11 billion in value.
NEW YORK and MELBOURNE, Australia, May 29, 2018-- Mesoblast Limited will report financial results for the quarter ended March 31, 2018 in a webcast beginning at 6:30 pm on Wednesday, May 30, 2018 EST; ...
Mesoblast Limited (MESO) (ASX:MSB) today announced that it has entered into a partnership with Cartherics Pty Ltd to develop allogeneic ‘off-the-shelf’ CAR-T cells armed with multiple targeting receptors for use in solid cancers. Off the shelf CAR-T therapies have the potential to reduce costs dramatically and open up this very effective treatment to millions of cancer patients across the world. The initial targets are relapsed ovarian and gastric cancers. Mesoblast and Cartherics will jointly own the intellectual property produced using their combined technologies.
The early hope that stem cell therapy would make the paralysed walk, the blind see and cure diabetes have given way to a long list of failures, highlighted by early stem cell champion Geron Corp abandoning the field in 2011. Both have overcome major hurdles to manufacturing stem cell treatments on a large scale that are off-the-shelf products derived from healthy donor bone marrow and do not face immune system rejection issues. Australia's Mesoblast, with a market value of about $US500 million ($A652.86 million), is attempting to alter advanced heart failure, a leading cause of hospitalisations and deaths and an enormous cost burden.